Loading…
← CockpitCompetitor Analysis › 300318.SZ Beijing Bohui Innovation Biotechnology Group Co. Ltd. Class AOpen in the cockpit ↗

Beijing Bohui Innovation Biotechnology Group Co. Ltd. Class A300318.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Momentum neutral 56
Mkt cap
$518M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$4.37M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-5.5 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥4.29
1D-1.4%
1W-5.3%
1M-10.4%
3M-15.9%
6M-19.5%
YTD-31.6%
1Y-26.8%
ATR %3.5%
52w lowhigh50.3% off high

What Beijing Bohui Innovation Biotechnology does

Employees: 2,170

Beijing Bohui Innovation Biotechnology at a glance

Size Beijing Bohui Innovation Biotechnology (300318.SZ) is a China Health Care company (Biotechnology) with a market value of $518M, the 3611th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.29 on 18 Nov 2026.

Performance Over six months the shares fell 19.5%, against -12.9% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 19 in its peer set.

Growth Revenue fell 1.5% over the last twelve months (peer median +3.1%); the operating margin is -13.1% (peer median -15.6%).

Valuation It trades at 6.2× enterprise value to sales against a peer median of 6.3× (7th cheapest of 15).

Capital Return on invested capital runs 5.5 points below its cost of capital (5.0% WACC).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 85300318.SZ 80
Six months, rebased to 100: Beijing Bohui Innovation Biotechnology against the median of its 20 peers (local-currency closes).

Beijing Bohui Innovation Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥822MCN¥820MCN¥848MCN¥1.04BCN¥792M
Revenue growth—-3%-19%+31%—
Gross profitCN¥330MCN¥269MCN¥350MCN¥379MCN¥174M
EBITDAn/aCN¥69.3MCN¥173MCN¥175MCN¥14.2M
Net income-CN¥82.9M-CN¥91.9MCN¥9.25M-CN¥24.9M-CN¥78.4M
Free cash flow-CN¥210M-CN¥292M-CN¥227M-CN¥60.5M-CN¥121M
Capital expenditureCN¥110MCN¥157MCN¥189MCN¥198MCN¥161M
Total debtCN¥908MCN¥1.13BCN¥1.06BCN¥814MCN¥794M

Quarterly statements and history in the cockpit →

Beijing Bohui Innovation Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%+100%VLA3008581521688247CLYMWVE6586SANACBIO4147MNPRGNFT1672FENC300318.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Bohui Innovation Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×2,500×5,000×7,500×VLA3008581521688247WVE6032556586300404GNFT1672FENC300318.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Bohui Innovation Biotechnology is the large dot.

Beijing Bohui Innovation Biotechnology competitors and peer comparison

How Beijing Bohui Innovation Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Bohui Innovation Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure300318.SZPeer medianRank in peer set
1-month return-10.4%-12.0%11th highest of 21
6-month return-19.5%-12.9%8th lowest of 19
Distance from 52-week high-50.3%-46.4%9th lowest of 21
Revenue growth (TTM)-1.5%+3.1%7th lowest of 15
Operating margin-13.1%-15.6%8th highest of 15
EV / Sales6.2×6.3×7th cheapest of 15
ROIC minus cost of capital-5.5 pp-3.8 pp5th lowest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
Frontage 1521.HKHong Kong$542M+113%+10%8%2.3×14.3%+15.4%
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%2.2×n/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%2.3×n/an/a
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%3.4×31.9%+27.2%
Genfit GNFT.PAFrance$571M+22%+28%-130%11.0×39.8%+143.5%
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%1,794.8×n/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a

Questions

Which companies are Beijing Bohui Innovation Biotechnology's closest peers?
The cockpit's peer set: LongBio Pharma (Suzhou) (1779.HK), Valneva (VLA.PA), Beijing Scitop Bio-Tech (300858.SZ), Frontage (1521.HK), Sinotherapeutics (688247.SS), Climb Bio (CLYM), Wave Life Sciences (WVE), Liaoning Dingjide Petrochemical (603255.SS).
Is Beijing Bohui Innovation Biotechnology expensive compared with its peers?
On ev / sales it trades at 6.2× against a peer median of 6.3×, 7th cheapest of 15 in its peer set.
How has Beijing Bohui Innovation Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -19.5% against -12.9% for the median peer; over one year -26.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.